Hossein Azadeh1, Reza Alizadeh-Navaei2, Alireza Rezaiemanesh3, Misagh Rajabinejad4,5. 1. Department of Internal Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. 2. Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran. 3. Department of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. 4. Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. misagh.ra@gmail.com. 5. Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, 18 km khazarabad, Sari, Iran. misagh.ra@gmail.com.
Abstract
BACKGROUND: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease characterized by immune system dysregulation and inflammation in the joints. Interleukin (IL)-17 inhibitors are new biological drugs used to treat AS. In this study, we aimed to assess the risk of immune system-related AEs due to targeting IL-17 or IL-17R. METHODS: The CENTRAL, PubMed, Scopus, Google Scholar, Clinical Trials Registry, and ICTRP were searched for randomized clinical trials (RCTs) and non-RCTs until February 2021. The risk of irAEs in patients treated with IL-17 inhibitors compared to the placebo or a drug-free control was evaluated. In studies that reported AEs of the IL-17 inhibitors at several different time points, we compared the number of cases/100 patient-year in which irAEs were reported. Subgroup analyses were also performed based on the dose and type of drugs. RESULTS: Thirteen studies of 1848 AS patients treated by IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, and netakimab) and 764 participants who received a placebo were included. The risk of some AEs related to immune function in patients under IL-17 inhibitors treatment was significantly higher than that of the placebo group, including infection and infestation (risk difference RD = 0.09, P = 0.02), nasopharyngitis (RD = 0.04, P < 0.001), opportunistic infections (RD = 0.01, P = 0.04), and neutropenia (RD = 0.04, P = 0.03). Besides, the results of the Cochran Q test showed that there were significant differences between the occurrence of some AEs over time, including infection and infestations (p < 0.001, RCTs), upper respiratory tract infections (p < 0.001, non-RCTs), urinary tract infections (p < 0.001, non-RCTs), and diarrhea (p < 0.01, RCTs). CONCLUSIONS: The most common immune system-related AEs in patients treated with IL-17 inhibitors are mucosal and opportunistic infections.
BACKGROUND: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease characterized by immune system dysregulation and inflammation in the joints. Interleukin (IL)-17 inhibitors are new biological drugs used to treat AS. In this study, we aimed to assess the risk of immune system-related AEs due to targeting IL-17 or IL-17R. METHODS: The CENTRAL, PubMed, Scopus, Google Scholar, Clinical Trials Registry, and ICTRP were searched for randomized clinical trials (RCTs) and non-RCTs until February 2021. The risk of irAEs in patients treated with IL-17 inhibitors compared to the placebo or a drug-free control was evaluated. In studies that reported AEs of the IL-17 inhibitors at several different time points, we compared the number of cases/100 patient-year in which irAEs were reported. Subgroup analyses were also performed based on the dose and type of drugs. RESULTS: Thirteen studies of 1848 AS patients treated by IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab, and netakimab) and 764 participants who received a placebo were included. The risk of some AEs related to immune function in patients under IL-17 inhibitors treatment was significantly higher than that of the placebo group, including infection and infestation (risk difference RD = 0.09, P = 0.02), nasopharyngitis (RD = 0.04, P < 0.001), opportunistic infections (RD = 0.01, P = 0.04), and neutropenia (RD = 0.04, P = 0.03). Besides, the results of the Cochran Q test showed that there were significant differences between the occurrence of some AEs over time, including infection and infestations (p < 0.001, RCTs), upper respiratory tract infections (p < 0.001, non-RCTs), urinary tract infections (p < 0.001, non-RCTs), and diarrhea (p < 0.01, RCTs). CONCLUSIONS: The most common immune system-related AEs in patients treated with IL-17 inhibitors are mucosal and opportunistic infections.
Authors: Dominique Baeten; Joachim Sieper; Jürgen Braun; Xenofon Baraliakos; Maxime Dougados; Paul Emery; Atul Deodhar; Brian Porter; Ruvie Martin; Mats Andersson; Shephard Mpofu; Hanno B Richards Journal: N Engl J Med Date: 2015-12-24 Impact factor: 91.245
Authors: Xenofon Baraliakos; Alan J Kivitz; Atul A Deodhar; Jürgen Braun; James C Wei; Eumorphia Maria Delicha; Zsolt Talloczy; Brian Porter Journal: Clin Exp Rheumatol Date: 2017-05-15 Impact factor: 4.473
Authors: Atul Deodhar; Philip G Conaghan; Tore K Kvien; Vibeke Strand; Bintu Sherif; Brian Porter; Steffen M Jugl; Kunal K Gandhi Journal: Clin Exp Rheumatol Date: 2018-07-19 Impact factor: 4.473
Authors: Xenofon Baraliakos; Juergen Braun; Atul Deodhar; Denis Poddubnyy; Alan Kivitz; Hasan Tahir; Filip Van den Bosch; Evie-Maria Delicha; Zsolt Talloczy; Anke Fierlinger Journal: RMD Open Date: 2019-09-03
Authors: Maxime Dougados; James Cheng-Chung Wei; Robert Landewé; Joachim Sieper; Xenofon Baraliakos; Filip Van den Bosch; Walter P Maksymowych; Joerg Ermann; Jessica A Walsh; Tetsuya Tomita; Atul Deodhar; Désirée van der Heijde; Xiaoqi Li; Fangyi Zhao; Clinton C Bertram; Gaia Gallo; Hilde Carlier; Lianne S Gensler Journal: Ann Rheum Dis Date: 2019-11-04 Impact factor: 19.103
Authors: Heather R Conti; Fang Shen; Namrata Nayyar; Eileen Stocum; Jianing N Sun; Matthew J Lindemann; Allen W Ho; Justine Hoda Hai; Jeffrey J Yu; Ji Won Jung; Scott G Filler; Patricia Masso-Welch; Mira Edgerton; Sarah L Gaffen Journal: J Exp Med Date: 2009-02-09 Impact factor: 14.307